SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies.
At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.
Location: France, Ile-de-France, Paris
Employees: 11-50
Total raised: $202.94M
Founded date: 2016
Investors 2
Date | Name | Website |
- | Jeito Capi... | jeito.life |
- | Ysios Capi... | ysioscapit... |
Funding Rounds 3
Date | Series | Amount | Investors |
18.09.2022 | Series B | $75.2M | Jeito Capi... |
14.09.2022 | Series A | $75M | UPMC Enter... |
27.10.2020 | - | $52.74M | - |
Mentions in press and media 13
Date | Title | Description | Source |
02.12.2022 | SparingVision’s lead asset SPVN06 clears IND application in ... | SparingVision set to advance into the clinic with breakthrough gene-independent approach targeting r... | 4biocapita... |
17.09.2022 | SparingVision Raises €75 Million Series B | LONDON– 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the tr... | 4biocapita... |
14.09.2022 | SparingVision Raises €75 Million Series B to Continue Buildi... | SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Me... | globenewsw... |
14.09.2022 | SparingVision Raises €75 Million Series B | LONDON– 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the tr... | 4biocapita... |
14.09.2022 | SparingVision Raises €75M in Series B Funding | SparingVision, a French biotech company, raised €75m in Series B funding. The round was co-led by J... | finsmes.co... |
10.06.2022 | 42 start-ups through to Catapult 2022-23 semifinals | We are excited to today announce the 42 promising start-ups that will go through to the semifinals o... | eithealth.... |
13.10.2021 | SparingVision announces strategic collaboration with Intelli... | London, 13 October 2020 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital fir... | 4biocapita... |
27.10.2020 | French startup SparingVision raises $52.6 million | French startup SparingVision raises $52.6 million 27 October, 2020, 15:00 Alexandra Minchuk -->... | ain.capita... |
21.10.2020 | 4BIO Capital leads SparingVision’s €44.5 million financing r... | - | 4biocapita... |
21.10.2020 | SparingVision cierra una ronda de €44,5M liderada por 4BIO C... | 21/10/2020 Nota de prensa YSIOS CAPITAL PARTICIPA EN LA RONDA DE FINANCIACIÓN DE €44,5 MILLONES DE... | webcapital... |
Show more